SCHEMBL3467749

SCHEMBL3467749

O=c1c2c(Cl)cc(Cl)c(O)c2nc(CCl)n1CC1CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B13 Q7Z5P4 1/20 0.37
PIM1 P11309 2/20 0.35
PIM3 Q86V86 2/20 0.35
PIM2 Q9P1W9 2/20 0.35
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
PDE5A O76074 1/20 0.32
BRD4 O60885 2/20 0.31
BAZ2A Q9UIF9 1/20 0.31
WDR5 P61964 1/20 0.31
GRM2 Q14416 2/20 0.30
NOX4 Q9NPH5 1/20 0.30
ADORA3 P0DMS8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7899042 0.86 HSD17B13 (0.35) HSD17B13PIM1PIM3PIM2ALDH1A1
SCHEMBL7903482 0.86 HSD17B13 (0.37) HSD17B13PIM1PIM3PIM2PDE4A
SCHEMBL7904228 0.85 NPC1 (0.39) HSD17B13ALDH1A1MEN1CYP3A4KMT2A
SCHEMBL7895830 0.84 HSD17B13 (0.36) HSD17B13PIM1PIM3PIM2PDE4A
SCHEMBL7903324 0.84 NPC1 (0.41) ALDH1A1SMN1; SMN2POLB
SCHEMBL7897273 0.84 HSD17B13 (0.36) HSD17B13PIM1PIM3PIM2ALDH1A1
SCHEMBL7897177 0.83 HSD17B13 (0.35) HSD17B13PIM1PIM3PIM2ALDH1A1
SCHEMBL7897324 0.82 CRHR1 (0.33) HSD17B13PIM1PIM3PIM2PDE4A
SCHEMBL7902018 0.82 HSD17B13 (0.35) HSD17B13PIM1PIM3PIM2PDE4A
SCHEMBL7896788 0.82 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
WO-2010071944-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 HSD17B13 2537/4885PIM1 3460/4885PIM3 2971/4885
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 HSD17B13 2552/4885PIM1 3444/4885PIM3 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.